微生物-宿主遗传互作经神经酰胺调控PNPLA3I148M携带者MASLD风险且可被靶向微生物干预逆转
研究用肝Pnpla3I148M表达合并Nlrp6缺陷的双打击小鼠模型,在西方饮食下结合多组学及三个人群队列,发现肠道屏障受损与菌群代谢物(长链神经酰胺和胆汁酸)升高协同加重肝损伤;FMT或Amuc_1100干预可改善肠道屏障并减轻肝脏脂质蓄积。
要点
- 肠道屏障受损可放大PNPLA3I148M相关肝损伤,是遗传外显率的上下文修饰因素
- 长链神经酰胺Cer(d18:1/16:0)和Cer(d18:1/18:0)及胆汁酸升高与肝线粒体应激和炎症相关
- FMT或Amuc_1100靶向微生物干预可改善肠道屏障并减轻肝脏脂质蓄积
核心结论
- 肠道屏障破坏产生的肠源性信号可能通过放大下游代谢和炎症反应来修饰PNPLA3I148M的临床外显率。
- 宿主-微生物界面是限制遗传高危个体MASLD进展的潜在干预靶点。
研究设计与样本
- 采用肝Pnpla3I148M表达合并Nlrp6缺陷的双打击小鼠模型,在西方饮食条件下进行多组学(宏基因组、代谢组、转录组)分析。
- 整合Lifelines、Charité MASLD、Human Phenotype Project三个人群队列进行分析。
- 通过粪菌移植(FMT)、抗生素清除和Akkermansia muciniphila或其膜蛋白Amuc_1100靶向干预检验菌群依赖效应。
主要发现
- 小鼠中Pnpla3I148M表达与肠道感知受损协同加重肠道屏障功能障碍和细菌侵入。
- 伴有门静脉中菌群相关代谢物升高,包括长链神经酰胺Cer(d18:1/16:0)、Cer(d18:1/18:0)和胆汁酸。
- 上述变化与肝脏线粒体应激和炎症反应相关;晚期MASLD人类携带者呈现与肠源性代谢信号增加一致的微生物和代谢特征。
- FMT或Amuc_1100治疗恢复优生菌群,改善肠道屏障完整性并减轻实验模型中的肝脏脂质蓄积。
临床怎么用
- 对PNPLA3I148M携带者,可关注肠道屏障功能与菌群代谢物(长链神经酰胺、胆汁酸)作为风险分层参考。
- 靶向微生物干预(如FMT或Amuc_1100)可能是限制遗传高危个体MASLD进展的策略,尚需临床验证。
局限性
- 机制证据主要来自双打击小鼠模型,人体数据为关联性分析,因果关系需进一步验证。
- FMT和Amuc_1100的干预效果仅在实验模型中观察,尚未在人群证实。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The factors that determine when genetic susceptibility to metabolic dysfunction-associated steatotic liver disease (MASLD) progresses to clinically significant liver injury remain incompletely understood. OBJECTIVE: We investigated whether disruption of the intestinal host-microbiota interface acts as a contextual modifier that amplifies PNPLA3I148M -associated hepatic injury. DESIGN: We used a dual-hit mouse model combining hepatic Pnpla3I148M -expression with Nlrp6-deficiency, a model of impaired intestinal mucosal homeostasis, under western-diet conditions. Multi-omics profiling, including metagenomics, metabolomics and transcriptomics, was integrated with analyses in human cohorts (Lifelines, Charité MASLD, Human Phenotype Project). Microbiota-dependent effects were examined using faecal microbiota transplantation (FMT), antibiotic-mediated depletion and targeted intervention with Akkermansia muciniphila or its membrane protein Amuc_1100. RESULTS: In mice, the combination of Pnpla3I148M expression and impaired intestinal sensing synergistically exacerbated gut-barrier dysfunction and bacterial encroachment, accompanied by increased portal levels of microbiota-associated metabolites, including long-chain ceramides (Cer(d18:1/16:0), Cer(d18:1/18:0)) and bile acids. These changes were associated with hepatic mitochondrial stress and inflammatory responses. Human carriers with advanced MASLD displayed microbial and metabolic signatures consistent with increased gut-derived metabolic signalling. Restoration of eubiotic microbiota via FMT or Amuc_1100 treatment improved intestinal barrier integrity and attenuated hepatic lipid accumulation in experimental models. CONCLUSION: These findings suggest that gut-derived signals resulting from a disrupted intestinal barrier may act as modifiers of PNPLA3I148M -clinical penetrance by amplifying downstream metabolic and inflammatory responses. By identifying these pathways linking environmental context to genetic susceptibility, this study highlights the host-microbiota interface as a potential target for strategies aimed at limiting MASLD progression in genetically at-risk individuals.
引用
- Haque M, Lesker TR, Rolle-Kampczyk U, et al. Microbiota-host genetic interactions modulate MASLD risk in PNPLA3I148M carriers via ceramides and are reversible by targeted microbial interventions. Gut. 2026. PMID: 42833873. doi:10.1136/gutjnl-2026-338178
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。